drugset
drugset / Trial / NCT03317899

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

NCT03317899 ↗

Phase 2 Completed 77 enrolled Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
RandomizedParallel-groupOpen-labelTreatment

Summary

This phase II trial studies how well stem cell transplant with or without tbo-filgrastim works in treating patients with multiple myeloma or non-Hodgkin lymphoma. Eliminating the use of tbo-filgrastim after transplant may still help maintain a similar time to discharge.

Timeline

Start
2017-10-12
Primary completion
2021-06-01
Completion
2022-11-16

Outcome

Met primary endpoint

registry analysis (non-inferiority test); Group I (auto HSCT tbo-filgrastim) vs Group II (auto HSCT); p = 0.001; Wilcoxon (Mann-Whitney) NCT03317899 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject filgrastim Protein / enzyme biologic — Subcutaneous

Indications

non-Hodgkin lymphoma plasma cell myeloma